![Karim Dabbagh](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Karim Dabbagh
Ordförande på
MAAT PHARMA
Förmögenhet: 851 362 $ per 2026-07-31
Profil
Karim Dabbagh was the founder of Modus Biomedicine, Inc., founded in 2009, and served as Chief Executive Officer from 2009 to 2010.
Current jobs include Chief Executive Officer at Dualitas Therapeutics, Inc. starting in 2026, and Independent Chairman at Maat Pharma SA starting in 2023.
Former job includes President, Chief Executive Officer & Director at Second Genome, Inc. from 2018 to 2023.
Education includes undergraduate studies at Imperial College London and a doctorate from University College London.
Kända innehav i offentliga företag
| Företag | Datum | Antal aktier | Värdering | Värderingsdatum |
|---|---|---|---|---|
MAAT PHARMA 1,41 % | 2025-03-31 | 266 173 ( 1,41 % ) | 851 362 $ | 2026-07-31 |
Aktiva positioner av Karim Dabbagh
| Företag | Position | Start |
|---|---|---|
| MAAT PHARMA | Ordförande | 2023-06-21 |
Tidigare kända positioner av Karim Dabbagh
| Företag | Position | Slut |
|---|---|---|
Second Genome, Inc.
 Second Genome, Inc. BiotechnologyHealth Technology Develops microbiome-based therapeutic products | Verkställande Direktör | 2023-09-01 |
Modus Biomedicine, Inc. | Verkställande Direktör | 2010-12-01 |
Karim Dabbaghs utbildningar
Erfarenheter
Innehade positioner
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Relationer
33
Första gradens relationer
5
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
Kopplade företag
| Privata företag | 5 |
|---|---|
Imperial College London
 Imperial College London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University College London
 University College London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Second Genome, Inc.
Second Genome, Inc. BiotechnologyHealth Technology Develops microbiome-based therapeutic products | Health Technology |
Maat Pharma SA
 Maat Pharma SA Pharmaceuticals: MajorHealth Technology Operates as a clinical stage company which develops and commercializes patient-microbiome symbiosis to improve survival outcomes in oncology | Health Technology |
Modus Biomedicine, Inc. |
